Utility values for chronic myelogenous leukemia chronic phase health states from the general public in the United Kingdom.
Leuk Lymphoma
; 53(5): 928-33, 2012 May.
Article
em En
| MEDLINE
| ID: mdl-21988666
ABSTRACT
This study estimated time trade-off preference values associated with the four chronic myelogenous leukemia (CML) chronic phase-related health states (i.e. untreated, hematologic response, cytogenetic response and molecular response) among members of the general public in the UK (n = 241). All four health states were associated with decreases in preference values from full health. The molecular response to treatment was the most preferred health state (mean utility of 0.94). The second-most preferred health state was cytogenetic response followed by hematologic response (mean utilities were 0.89 and 0.80, respectively). The least preferred health state was untreated chronic phase CML (mean utility of 0.72). The utility values for each state were significantly different from one another (p < 0.001). This study demonstrated and quantified the impact that more robust treatment responses have on the health-related quality of life of patients with chronic phase CML.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Leucemia Mieloide de Fase Crônica
/
Indicadores Básicos de Saúde
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article